Overview

* Tenet Healthcare Q2 2025 revenue rises 3.2%, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 2025 up 74%, surpassing consensus, per LSEG data

* Co authorizes $1.5 bln increase to share repurchase program

Outlook

* Tenet raises FY 2025 adjusted EBITDA outlook to $4.40 bln-$4.54 bln

* Company expects FY 2025 net operating revenues of $20.95 bln-$21.25 bln

* Tenet forecasts FY 2025 adjusted EPS of $15.55-$16.21

* Company projects FY 2025 free cash flow of $2.025 bln-$2.275 bln

Result Drivers

* SAME-FACILITY REVENUE - Growth driven by higher acuity and favorable payer mix

* MEDICAID IMPACT - Hospital segment benefited from $79 mln favorable pre-tax impact from Medicaid supplemental revenues

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $5.27 $5.16

Revenue bln bln (17

Analysts

)

Q2 Beat $4.02 $2.87

Adjusted (18

EPS Analysts

)

Q2 EPS $3.14

Q2 Net $288 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Tenet Healthcare Corp ( THC ) is $191.50, about 8.8% above its July 21 closing price of $174.65

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)